GSK is witnessing increased sales growth of its Specialty Medicines unit, a trend expected to continue through the rest of 2025.

GSK specialty medicines grew YoY in Q1 2025, and it is now the main profit engine, offsetting the weakness in their vaccine ...

Nucala is already approved for several indications, including eosinophilic asthma, and brought in £1.78 billion (around $2.4 billion) in sales last year. GSK has suggested that approval in COPD ...

Sanofi and Regeneron, AstraZeneca, Roche’s Genentech and GSK have provided support for the Living Well with COPD educational ...

GSK just hit one of its main objectives for 2025 after getting FDA approval of anti-IL-5 antibody Nucala as a treatment for chronic obstructive pulmonary disease (COPD).

GSK stock is up 21.5% in six months, fueled by strong Specialty Medicines growth and a promising pipeline despite vaccine headwinds.

Merck has pulled off another acquisition which fits in its “sweet spot,” as described by CEO Rob Davis, paying $10 billion ...

GSK’s pentavalent MenABCWY meningococcal vaccine and Blujepa/gepotidacin for treating uncomplicated urinary tract infection (“UTI”) were approved in the United States in the first quarter of 2025. Its ...